Leuprorelin Acetate

• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended
  2023-503995-26-00 Phase III 13 countries AstraZeneca AB
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• Darolutamide vs ADT in hormone naïve Pca Ended
  2024-510840-30-00 Phase II 4 countries European Organisation For Research And Treatment Of Cancer
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended
  2024-516204-42-00 Phase III 1 country BOOG Study Center B.V.
• A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris… Ended
  2024-513450-30-00 Phase III 3 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended
  2024-513521-23-00 Phase III 10 countries Medivation Inc.
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended
  2024-515171-35-00 Phase III 1 country Unicancer
• Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C… Ended
  2023-509167-24-00 Phase II 2 countries Novartis Pharma AG
• The AGAINST-PLD Study; An investigator-driven, randomized, open label clinical trial assessing efficacy of leuprorelin to halt disease progr… Ended
  2023-506637-30-00 Phase III 1 country Universitair Medisch Centrum Groningen

Showing 25–33 of 33 trials